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The samples were subjected to mass spectrometric analysis after
pre-separation by UHLC Ultimate 3000 RS (Dionex, USA) in a col-
umn Dionex Acclaim RSLC 120 C18 (2.1  50 mm 120 A, 0.2 lm)
flow rate of 0.5 ml/min using as eluents 0.1% solution of formic
acid in water (A) and 0.1% solution of formic acid in atsetontrile
(B). Elution was carried out in gradient mode: (%B): 0–3min (5%),
3–28min (5–95%), 28–30 min (95%), 30–31 min (95–5%), 31–35 min
(5%). Mass spectrometry was carried out on ESI-qTOF ultrahigh
resolution Maxis 4G (Bruker, Germany) in the positive ion detec-
tion mode range 50–1000 m/z, 2 Hz with the following settings
electrospray ion source: CV 3800 V, Nebulizer gas 1 bar, Dry Gas
8 l/min, Dry Temp: 200 C.
Results: It was found that the DNA which was cleaved with
acid hydrolysis in the result contained single DNA bases. The
samples were stable at 4 C for at least 7 days. The optimal eluent
for solid phase extraction of DNA is 80% solution of methanol in
water. The number of DNA adducts was evaluated by the inte-
grated value of the mass spectrometric response detector. It
was shown that most amount of adducts 4-hydroxy-1-(3-
pyridyl)-1- butanone and N3-(2-carbamoyl-2-hydroxyethyl)ade
nine was found in DNA samples derived from tumor tissue. The
adduct N7-(2-carbamoyl-2-hydroxyethyl)guanine was found in
tumor tissue samples and DNA derived from plasma, as well as
in all samples of healthy tissue.
Conclusion: The established protocol of DNA sample prepara-
tion followed by analysis using a mass spectrometer high resolu-
tion allows to detect the content of the DNA adducts in small DNA
probes (100 ng). We found, that acid hydrolysis is cheaper and
more practical in comparison to enzymatic digestion in order to
generated samples containing single DNA bases without damag-
ing the structure of adducts.
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Mutations in BRCA1 and CHEK2 genes associated with
hereditary breast cancer were tested in 7920 randomly selected
individuals of Novosibirsk (Russia). Mutations BRCA1 5382insC
and CHEK2 1100delC were the most frequent, they were found
in 0.25% and 0.4% of the general population respectively. We
suggested to find mutations carriers by the screening of all
breast/ovary cancer patients for the most frequent mutations
(BRCA1 5382insC and CHEK2 1100delC) with subsequent analysis
of the first-line relatives of cancer patients if one of the mutations
was found.
From June 2013 till January 2015, all patients from Novosibirsk
regional oncology hospital with the diagnosis of breast cancer
and some patients with the diagnosis of ovary cancer were tested
for mutations BRCA1 5382insC and CHEK2 1100delC. A total of
2655 cancer patients were analyzed independently of their family
history. We found 122 mutations carriers, among them 99
patients with mutations in BRCA1 gene and 23 patients with
mutation CHEK2 1100delC. Among mutation carriers, 105 patients
agreed to have a medical genetic counseling and after pedigree
analysis 193 first-line relatives aged above 25 years were eluci-
dated. One hundred ten first-line relatives of mutation carriers
were analyzed for the mutations presence and 40 mutations car-
riers were found among relatives.
From September 2013 till December 2013, 32 relatives of BRCA
mutation carriers underwent breast MRI. In 5 cases, breast can-
cer was detected by MRI and all cancers except one were con-
firmed histologically with biopsy analysis. Importantly, all
tumors were 5 mm and less in size, stage I cancer was detected
in all cases.
At a follow-up of 1.5 years, all 105 mutation carrier probands
were interviewed by phone regarding possible relapse and/or
possible primary cancer in their relatives. Five of 105 probands
lost to follow-up may have died. Among responding 100 patients,
2 died as reported by relatives, relapse was reported in 7 probands
– mutation carrier probands, primary tumors were reported in 8
relatives of probands.
Mutation carrier probands reported one bilateral breast
cancer, four ovary cancers, one bladder cancer and one non-
specified oncogynecological tumor.
There were five cases of primary breast cancer, one ovary can-
cer, one colon cancer, one lung cancer among relatives of breast
cancer patients with mutations. The frequency of tumors found
in mutation carriers exceeded the average frequencies of cancer
for this population.
The economic value of the regional genetic screening can be
easily estimated according to the data obtained in this study
and data on treatment cost for stage I and stage IV breast cancer.
To summarize briefly, the screening of hot-spot mutations
provides not only increase of lifespan expectancy and life quality
for mutation carriers, but can be also a tool for financial saving of
medical system due to the increase of early stage breast cancer
detection.
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